aibioBy aibio.space
Protara has 26 months of cash on paper, early data and plans that need more money
Protara has $142.5 million and a bladder cancer trial with small, open-label, uncontrolled interim data whose response rate fell by half between six and 12 months. Spending is rising, and the company says it will need new capital.
TARA Mixed view The bladder cancer data are interesting, but the cash plan is thin: spending is rising and the company says it will need to raise more money.
Protara Therapeutics is a clinical-stage company based in New York City. Its lead program, TARA-002, targets bladder cancer and lymphatic malformations. At June 30, 2026 it had $142.5 million of cash, cash equivalents and short-term investments. Our arithmetic gives about 26 months of cash at its four-quarter average burn. We think the cash plan is the weak link, and our view is that the company will need to raise money again.
What the company does and where it is
The latest annual report describes a company committed to advancing therapies for cancer and rare diseases. Its lead oncology program is TARA-002 in non-muscle invasive bladder cancer, or NMIBC. TARA-002 is based on OK-432, and the filing says the cell therapy is approved in Japan and Taiwan for lymphatic malformations and multiple oncologic indications. Neither TARA-002 nor the company's other program, IV Choline Chloride, has been approved by the FDA or comparable regulators for any indication.
The lead trial is ADVANCED-2, a Phase 2 open-label study in high-grade carcinoma in situ, or CIS. Cohort A has enrolled 31 patients. Cohort B is expected to enroll 75 to 100 patients with BCG-Unresponsive CIS. The company expects to finish enrolling Cohort B in the second half of 2026.
In the BCG-Unresponsive cohort, the CR rate at any time was 65.7% (23/35). The rate at any time counts a complete response at any visit, including ones later lost, so it flatters the picture. At six months the rate was 68.2% (15/22), and at 12 months it was 33.3% (5/15), per the quarterly report. Only fifteen patients had reached the 12-month mark. The study is open-label with no control arm, and the company reports that no patient stopped treatment because of treatment-related adverse events and that there were no Grade 3 or higher treatment-related events, as assessed by the study investigators. The data cutoff was January 28, 2026, and the safety group is 74 patients. We treat the results as a signal, not proof.
The field is crowded. The annual report lists BCG as the standard of care and, among approved NMIBC products, Keytruda, Adstiladrin, VesAnktiva with BCG and Inlexzo, with more candidates in development. A single-arm response rate in a small cohort has to stand next to those drugs. The BCG-Unresponsive cohort that would support registration is still enrolling, and the BCG-Naïve controlled trial, ADVANCED-3, has not started.
Cash and burn
Our runway arithmetic is simple. $142.5 million divided by $16.5 million a quarter is 8.6 quarters, or about 26 months of cash at that rate. The $16.5 million is the average quarterly operating cash outflow over the last four quarters. We leave out $19.4 million of long-term investments, which that figure does not count.
On the same measure, cash was $155.6 million at December 31, 2025, and $142.5 million at June 30, 2026.
Operating cash outflow was $12.5 million in the quarter ended September 30, 2025, $16.9 million in the quarter ended December 31, 2025, $21.3 million in the quarter ended March 31, 2026, and $15.4 million in the quarter ended June 30, 2026. The last two quarters average $18.4 million. At that rate the same cash lasts less time. On this cash measure, we think 26 months is the upper end of what recent spending supports.
What management says about its cash
The company's own statement is more cautious than our arithmetic. The quarterly report says the company believes its resources are sufficient for at least 12 months from the date of issuance of its financial statements. We think the gap may come from the plan. The filing says the company will need to raise additional capital in order to fully realize management's plans. It also says it may need to curtail planned development activities if it cannot raise additional capital.
Research costs have risen in each of the last three quarters, so that assumption is doubtful.
The financing record is long. The company sold approximately $102.8 million gross in December 2024 and approximately $86.3 million gross in December 2025, both under its shelf registration. Warrant exercises brought in $5.7 million, and the remaining unexercised warrants expired on June 29, 2026. In May 2026 the company filed a new $300.0 million shelf and signed a sales agreement for up to $100.0 million of common stock with TD Securities. As of June 30, 2026, no shares had been sold under that program.
The filing's own liquidity paragraph gives a higher number, $161.9 million of unrestricted cash and cash equivalents and marketable debt securities. We use the lower $142.5 million balance sheet figure, which leaves out long-term investments. The filing does not reconcile the two.
Where the money goes
Research and development is the largest cost, and it is climbing. R&D was $17.0 million in the quarter ended June 30, 2026, against $10.8 million a year earlier. The company attributes the $6.2 million increase to a $3.2 million rise in direct costs for its product candidates and a $3.0 million rise in indirect costs. Six-month R&D was $30.5 million, up $10.6 million.
General and administrative expense was $6.4 million in the quarter, an increase of approximately $0.6 million. Quarterly net loss rose from $13.3 million in the quarter ended September 30, 2025 to $21.7 million in the quarter ended June 30, 2026. In the first half of 2026 the company used $36.7 million in operating cash against a net loss of $39.5 million.
The bull case
The bull case rests on the NMIBC data, the regulatory feedback and the cash on hand. For the BCG-Naïve cohort, the CR rate at any time was 72.4% (21/29), 66.7% (18/27) at six months and 57.9% (11/19) at 12 months. The company says the FDA agreed that BCG is not required as a comparator in a planned controlled trial for BCG-Naïve patients, and that intravesical chemotherapy is an acceptable comparator. The cohort includes patients who cannot or will not take BCG, so the comparison is with chemotherapy, not with BCG. With $142.5 million on hand and a new $300.0 million shelf registration, management has room to raise more money.
The bear case
The bear case is the burn and the money. Operating cash outflow reached $21.3 million in the quarter ended March 31, 2026. The company has no revenue and says it may never generate any. Its filing says it does not know whether additional capital will be available when needed. We think the durability data are thin. The BCG-Unresponsive CR rate fell from 68.2% (15/22) at six months to 33.3% (5/15) at 12 months, and that is the cohort the company wants to use for registration. The warrant source is used up, since the remaining warrants have expired. A second product, IV Choline Chloride, is in a registrational Phase 2b/3 trial that began in January 2026 and adds to costs.
Our view
We think the bear case is stronger on money, and no better than even on the science. The FDA feedback, as the company describes it, is a real step on trial design, but it is not a sign that the drug works. The data are open-label, uncontrolled and small, and the 12-month result is weak. The cash plan is the weak link. Our 26-month figure holds only if spending stays where it is, and spending is rising. Our view is that Protara will need new money before its current cash runs out, and the at-the-market program is the likeliest first source. This is opinion, not investment advice.
What to watch, and what would change our mind
Enrollment of the BCG-Unresponsive registrational cohort. Quarterly operating cash outflow, after $15.4 million in the quarter ended June 30, 2026. Any sales under the at-the-market program, and any offering under the new $300.0 million shelf. Whether R&D keeps climbing. What would change our mind: operating outflow back near the four-quarter average of $16.5 million for several quarters, a financing that covers the registrational cohort, or a statement that the runway is well beyond 12 months.